ADRB2 and sarcoma: Moreover, because the expression does not indicate that these sarcomas are responsive to β-receptor antagonists, as a proof of concept, we explored whether the β-AR antagonist propranolol resulted in therapeutic efficacy and an enhanced response to standard chemotherapeutics in cell models of LMS and LPS by investigating putative mechanisms underlying the effectiveness of combinations.